Feilim Mac Gabhann
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (8)
The endometrium and menstrual disorders, such as endometriosis and adenomyosis, are difficult to study, partly because menstruation depends on interactions between multiple cell types through complex molecular mechanisms. To help understand this system, researchers need humanized experimental and computational models that can interrogate how endometrial cell populations impact each other in both physiological and pathological conditions. Here, we use ordinary differential equations (ODEs) to model changes in the rates of endometrial cell proliferation and death in response to hormones, cytokines, and the specific cell types present. To calibrate this computational model, we used previously-published experimental datasets from a 3D co-culture platform supporting primary human endometrial epithelial organoids and endometrial stromal cells. Our ODE-based model can simulate the size of endometrial epithelial organoids and the density of stromal cells over time under multiple hormone/cytokine conditions in mono- and co-cultures. We further created a second, partial differential equation (PDE)-based model that simulates the diffusion of molecules added to these 3D cultures and their uptake by proliferating endometrial cells using the predicted cell densities from the ODE model as inputs to the PDE simulations. We show that the exposure to hormones and cytokines used in the experiments is reasonably homogenous throughout the 3D culture and identify conditions where this would not be true. Altogether we use these models to quantify the influence of stromal cells on epithelial cell proliferation and vice versa , to identify differences across cells from different donors, and to provide a quantitative assessment of experimental designs.
Year:
2025
Constitutively secreted by endothelial cells, soluble FLT1 (sFLT1 or sVEGFR1) binds and sequesters extracellular vascular endothelial growth factors (VEGF), thereby reducing VEGF binding to VEGF receptor tyrosine kinases and their downstream signaling. In doing so, sFLT1 plays an important role in vascular development and in the patterning of new blood vessels in angiogenesis. Here, we develop multiple mechanistic models of sFLT1 secretion and identify a minimal mechanistic model that recapitulates key qualitative and quantitative features of temporal experimental datasets of sFLT1 secretion from multiple studies. We show that the experimental data on sFLT1 secretion is best represented by a delay differential equation (DDE) system including a maturation term, reflecting the time required between synthesis and secretion. Using optimization to identify appropriate values for the key mechanistic parameters in the model, we show that two model parameters (extracellular degradation rate constant and maturation time) are very strongly constrained by the experimental data, and that the remaining parameters are related by two strongly constrained constants. Thus, only one degree of freedom remains, and measurements of the intracellular levels of sFLT1 would fix the remaining parameters. Comparison between simulation predictions and additional experimental data of the outcomes of chemical inhibitors and genetic perturbations suggest that intermediate values of the secretion rate constant best match the simulation with experiments, which would completely constrain the model. However, some of the inhibitors tested produce results that cannot be reproduced by the model simulations, suggesting that additional mechanisms not included here are required to explain those inhibitors. Overall, the model reproduces most available experimental data and suggests targets for further quantitative investigation of the sFLT1 system.
Year:
2025
Lymphocytes rely on cell motility to surveil immune microenvironments and engage in contact-mediated interactions with other cells as part of the adaptive immune response. Within the germinal center (GC) light zone, germinal center B-cells (GCBs) and T-follicular helper cells (Tfhs) engage in cell-cell interactions that enable antibody affinity maturation. The number and duration of GCB-Tfh interactions correlate with the success of the germinal center in effectively generating antibodies that can bind and neutralize antigens. Prior studies have shown that GCBs and Tfhs exploit distinct motility patterns to surveil the GC light zone and engage in these cell-cell interactions. However, the quantitative relationship between lymphocyte motility parameters (such as speed and tortuosity) and GCB-Tfh interactions has not been systematically explored. Here, we analyzed single-cell trajectories of GCBs and Tfhs from two-photon intravital microscopy videos of GCs within mouse popliteal lymph nodes. We found that these cells exhibit seven distinct motility behaviors, each with characteristic speeds and tortuosities. GCBs tended to move in slow and tortuous paths, while Tfhs adopted faster and more directed trajectories. We then developed a three-dimensional agent-based model (ABM) to simulate these experimentally-observed GCB and Tfh motility behaviors and predict their impact on GCB-Tfh interactions. Using the ABM, we found that the baseline motility behaviors of GCBs and Tfhs allow GCBs to maximize interactions with distinct Tfhs in a confined space.
Year:
2025
While HIV can be effectively suppressed to a chronic, mostly asymptomatic infection with combination antiretroviral therapy (cART), a cure is still needed. Hematopoietic stem cell transplantation (HSCT) from HIV-resistant donors has shown promise and has resulted in HIV remission in five patients. However, this treatment strategy does not guarantee HIV remission; six other patients who received a similar transplant had poor outcomes and died within a year of treatment. These different outcomes may be due to inter-individual differences in HIV infection dynamics that result in heterogeneity of therapeutic responses to HSCT. Using a previously published mechanistic model of HIV infection and virtual populations calibrated from patient data, we performed simulations to understand how different parameters in the model can influence the observed heterogeneity in therapeutic outcomes across virtual patient populations. Our simulations confirmed that discontinuation of cART, without HSCT, always leads to viral rebound, and that time to rebound differs across patients due to the interindividual variability (IIV) in underlying infection dynamics. Extending the duration of cART only slightly increased the predicted median time to rebound and its variance. By contrast, HSCT followed by cART cessation led to HIV remission, but only for a subset of the virtual patients. The proportion of patients predicted to go into remission depends directly on the ratio of donor to host cell immune cells in the post-HSCT chimeric immune system. Of the mechanistic model parameters, no single parameter determined whether a patient was a responder or a non-responder; rather, the interactions between multiple model parameters were crucial in driving treatment responses. In contrast, virtual equivalents of clinically accessible observations, e.g. viral load and cell populations at specific times, were shown to be better predictors than mechanistic model parameters in separating patients into non-responding (viral rebound) and responding (no rebound) clusters. One Sentence Summary Simulations using a mechanistic HIV model suggest that interindividual variability (IIV) in infection dynamics drives differential responses to hematopoietic stem cell transplantation (HSCT), with HIV remission being largely dependent on donor-to-host immune cell ratios in the post-HSCT chimeric immune system and better predicted by clinically accessible observations than individual model parameters.
Year:
2025
Antibody-drug conjugates (ADCs) are novel therapeutics combining two molecules linked together: an antibody that provides targeting to specific cells, and a cytotoxic drug (warhead) that can deconjugate from the antibody and kill those cells. The warhead by itself would be too nonspecific and toxic; the antibody by itself would be insufficiently effective at killing the cells. As more and more ADCs enter the drug development pipeline, understanding the mechanistic reasons behind efficacy and toxicity is critical to evaluating both successful and failed trials. Here, we have developed a mechanistic computational model of ADCs, and specifically parameterize it using data for MEDI2228, an anti-BCMA antibody conjugated to pyrrolobenzodiazepine (PBD) warheads. We build the model to track not only the concentrations of ADC and its released warhead drug inside and outside the cell, but also to track the recent history of the warhead, so that we can distinguish between pathways for on-target and bystander (nontargeted) cell killing. We show that this effect is predicted to be small under in vitro conditions due to dilution in large volumes of media, but likely to form a significant part of both targeted and nontargeted cell killing in vivo , where the extracellular volume has less of a dilution effect. We also explore the impact of key design parameters of ADCs, including drug to antibody ratio (DAR), warhead potency, and lipophilicity; this analysis demonstrates the balance needed between killing of targeted and nontargeted cells. Using this quantitative systems pharmacology model, we can generate insights for optimization of ADC design and determine which factors are most critical to efficacy and toxicity, leading to more informed and rational development of cancer therapies.
Year:
2025
Constitutively secreted by endothelial cells, soluble FLT1 (sFLT1 or sVEGFR1) binds and sequesters extracellular vascular endothelial growth factors (VEGF), thereby reducing VEGF binding to VEGF receptor tyrosine kinases and their downstream signaling. In doing so, sFLT1 plays an important role in vascular development and in the patterning of new blood vessels in angiogenesis. Here, we develop multiple mechanistic models of sFLT1 secretion and identify a minimal mechanistic model that recapitulates key qualitative and quantitative features of temporal experimental datasets of sFLT1 secretion from multiple studies. We show that the experimental data on sFLT1 secretion is best represented by a delay differential equation (DDE) system including a maturation term, reflecting the time required between synthesis and secretion. Using optimization to identify appropriate values for the key mechanistic parameters in the model, we show that two model parameters (extracellular degradation rate constant and maturation time) are very strongly constrained by the experimental data, and that the remaining parameters are related by two strongly constrained constants. Thus, only one degree of freedom remains, and measurements of the intracellular levels of sFLT1 would fix the remaining parameters. Comparison between simulation predictions and additional experimental data of the outcomes of chemical inhibitors and genetic perturbations suggest that intermediate values of the secretion rate constant best match the simulation with experiments, which would completely constrain the model. However, some of the inhibitors tested produce results that cannot be reproduced by the model simulations, suggesting that additional mechanisms not included here are required to explain those inhibitors. Overall, the model reproduces most available experimental data and suggests targets for further quantitative investigation of the sFLT1 system. Author Summary Proteins that are typically found outside cells are initially made inside cells, and later secreted into extracellular space. Many of these secreted proteins have important functions outside the cell that are well-studied; however, usually much less is known about the pre-secretion life of these molecules. Many computational models only represent the extracellular versions of secreted proteins, reducing all production and secretion steps into a single modeled process. Here, we develop a mechanistic model of the production and secretion of a specific secreted protein, sFLT1, which inhibits blood vessel growth by acting as an extracellular sponge for another set of secreted proteins, the vascular endothelial growth factors. We compare several models to existing experimentally-measured sFLT1 data, and we show that the data are most simply explained by including a delay between intracellular sFLT1 production and sFLT1 transport or degradation. This is consistent with the biology of the cell’s secretory pathway, where immature proteins are gradually processed into mature forms over minutes to hours. Our approach could be incorporated into improved models for any pathway involving secreted proteins, including sFLT1-regulated models of blood vessel biology.
Year:
2025
The vascular endothelial growth factor receptors (VEGFRs) bind to cognate ligands to facilitate signaling pathways critical for angiogenesis, the growth of new capillaries from existing vasculature. Intracellular trafficking regulates the availability of receptors on the cell surface to bind ligands, which regulate activation, and the movement of activated receptors between the surface and intracellular pools, where they can initiate different signaling pathways. Using experimental data and computational modeling, we recently demonstrated and quantified the differential trafficking of three VEGF receptors, VEGFR1, VEGFR2, and coreceptor Neuropilin-1 (NRP1). Here, we expand that approach to quantify how the binding of different VEGF ligands alters the trafficking of these VEGF receptors and demonstrate the consequences of receptor localization and ligand binding on the localization and dynamics of signal initiation complexes. We include simulations of four different splice isoforms of VEGF-A and PLGF, each of which binds to different combinations of the VEGF receptors, and we use new experimental data for two of these ligands to parameterize and validate our model. We show that VEGFR2 trafficking is altered in response to ligand binding, but that trafficking of VEGFR1 is not; we also show that the altered trafficking can be explained by a single mechanistic process, increased internalization of the VEGFR2 receptor when bound to ligand; other processes are unaffected. We further show that even though the canonical view of receptor tyrosine kinases is of activation on the cell surface, most of the ligand-receptor complexes for both VEGFR1 and VEGFR2 are intracellular. We also explore the competition between the receptors for ligand binding, the so-called ‘decoy effect’, and show that while in vitro on the cell surface minimal such effect would be observed, inside the cell the effect can be substantial and may influence signaling. We term this location dependence the ‘reservoir effect’ as the size of the local ligand reservoir (large outside the cell, small inside the cell) plays an integral role in the receptor-receptor competition. These results expand our understanding of receptor-ligand trafficking dynamics and are critical for the design of therapeutic agents to regulate ligand availability to VEGFR1 and hence VEGF receptor signaling in angiogenesis.
Year:
2024
Antibody‐drug conjugates (ADCs) have gained traction in the oncology space in the past few decades, with significant progress being made in recent years. Although the use of pharmacometric modeling is well‐established in the drug development process, there is an increasing need for a better quantitative biological understanding of the pharmacokinetic and pharmacodynamic relationships of these complex molecules. Quantitative systems pharmacology (QSP) approaches can assist in this endeavor; recent computational QSP models incorporate ADC‐specific mechanisms and use data‐driven simulations to predict experimental outcomes. Various modeling approaches and platforms have been developed at the in vitro, in vivo, and clinical scales, and can be further integrated to facilitate preclinical to clinical translation. These new tools can help researchers better understand the nature and mechanisms of these targeted therapies to help achieve a more favorable therapeutic window. This review delves into the world of systems pharmacology modeling of ADCs, discussing various modeling efforts in the field thus far.
Year:
2022
Collaborators (4)
Sarvenaz Sarabipour
Assistant Professor
University of Connecticut Health Center
Victoria L. Bautch
University of North Carolina at Chapel Hill
Brian Annex
Professor and Chair
Augusta University Medical College of Georgia
Juan Sebastian Gnecco
Assistant Professor
Tufts University
Make your next move.
Prepare your application
Review drafts before you send them.